Adagio Medical Holdings Inc (ADGM) FinancialsADGMFinancialAdagio Medical Holdings Inc

Evaluating the bottom line, Adagio Medical Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -657.76%, provide a clear picture of how effectively ADGM converts its operational activities into shareholder value.

In the context of the broader market, ADGM competes directly with industry leaders such as HSCS and IRIX. With a market capitalization of $13.11M, it holds a significant position in the sector. When comparing efficiency, ADGM's gross margin of N/A stands against HSCS's 59.06% and IRIX's 34.19%. Such benchmarking helps identify whether Adagio Medical Holdings Inc is trading at a premium or discount relative to its financial performance.

Adagio Medical's financial performance shows a troubling trend with a net income of -$7 million in Q1 2026 and a gross margin of -208.65% in Q3 2024, indicating severe operational challenges. The company has not generated revenue for several quarters, which is alarming for potential investors.